Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
European Central Bank's overnight loans drop to zero, with €222 trillion in deposits as markets hoard cash to cope with uncertainty

European Central Bank's overnight loans drop to zero, with €222 trillion in deposits as markets hoard cash to cope with uncertainty

汇通财经汇通财经2026/06/04 09:35
Show original
⑴ Data released by the European Central Bank on Thursday show that financial institutions did not borrow any funds through the overnight lending facility, with usage at zero, compared to 1 million euros on the previous trading day. Meanwhile, usage of the overnight deposit facility rose to 2,221.687 billion euros, higher than the previous trading day’s 2,196.400 billion euros. ⑵ Current account holdings stand at 169.058 billion euros, a slight decrease from 172.594 billion euros on the previous trading day. The size of the deposit facility far exceeds that of the lending facility, reflecting financial institutions’ preference to park excess liquidity at the European Central Bank to earn returns rather than lending it out or taking on credit risk. ⑶ From a trading sentiment perspective, the zero demand for overnight lending combined with the continued growth of deposit holdings indicates that market participants are actively shrinking their balance sheets and have a strong preference for holding cash. Coupled with global trade concerns triggered by Trump’s tariff comments, funds are opting to stay on the sidelines rather than being allocated to risk assets, and the market as a whole remains defensive.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage

Eli Lilly stated on Monday that its oral weight-loss drug, Foundayo, has captured over 30% of the market share among new patients in the US oral obesity treatment market, narrowing the early lead achieved by Danish competitor Novo Nordisk with its Wegovy oral tablets.

智通财经2026/09/15 03:21
Competition in US oral weight-loss drugs intensifies! Eli Lilly (LLY.US) Foundayo captures 30% of new patients, narrowing Novo Nordisk's (NVO.US) first-mover advantage